Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Decrease in immunoreactivity in melanoma. Analysis of DNCB tests in the literature].

W Remy, R Dorn, K Ulm

    Zeitschrift Fur Hautkrankheiten
    |December 15, 1986
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Readmission after surgery: are neuromuscular blocking drugs a cause?

    British journal of anaesthesia·2017
    Same author

    Sugammadex and neostigmine dose-finding study for reversal of residual neuromuscular block at a train-of-four ratio of 0.2 (SUNDRO20)†,.

    British journal of anaesthesia·2016
    Same author

    [Antegrade scrotal sclerosis therapy. Gold Standard of varicocele treatment].

    Der Urologe. Ausg. A·2015
    Same author

    Impingement-free range of movement, acetabular component cover and early clinical results comparing 'femur-first' navigation and 'conventional' minimally invasive total hip arthroplasty: a randomised controlled trial.

    The bone & joint journal·2015
    Same author

    Influence of pollen feeding and physiological condition on pesticide sensitivity of the honey bee Apis mellifera carnica.

    Oecologia·2014
    Same author

    Diagnostic value and therapeutic impact of (18)F-FDG-PET/CT in differentiated thyroid cancer. Results of a German multicentre study.

    Nuklearmedizin. Nuclear medicine·2012
    Same journal

    [Acne vulgaris: morphologic, endocrinologic and psychosomatic aspects].

    Zeitschrift fur Hautkrankheiten·1990
    Same journal

    [Anti-androgen treatment of hirsutism with cyproterone acetate].

    Zeitschrift fur Hautkrankheiten·1990
    Same journal

    [Changes in sunscreening products in West Germany between 1988 and 1989/90].

    Zeitschrift fur Hautkrankheiten·1990
    Same journal

    [Effect of treatment with salt from the Dead Sea (Tomesa therapy) on epidermal Langerhans cells--a clinical study].

    Zeitschrift fur Hautkrankheiten·1990
    Same journal

    [DNA determination by cytophotometry in bowenoid papules in comparison with condylomata acuminata and Bowen's disease].

    Zeitschrift fur Hautkrankheiten·1990
    Same journal

    [Adverse drug reactions on hair].

    Zeitschrift fur Hautkrankheiten·1990
    See all related articles

    Melanoma impairs cell-mediated immunity, with DNCB sensitization decreasing significantly as cancer progresses. This supports immune modulation therapies for melanoma patients.

    Area of Science:

    • Immunology
    • Oncology
    • Dermatology

    Background:

    • Cell-mediated immunity is widely believed to be compromised in melanoma patients.
    • Some studies challenge this notion, particularly in early-stage cancers.

    Purpose of the Study:

    • To systematically evaluate the literature regarding DNCB (2,4-dinitrochlorobenzene) skin test results in melanoma patients.
    • To assess the relationship between tumor progression and immune response in melanoma.

    Main Methods:

    • Literature review and meta-analysis of studies reporting DNCB skin test results in melanoma patients.
    • Comparison of DNCB sensitization rates between different melanoma stages and healthy controls.

    Main Results:

    • DNCB sensitization showed a linear decrease with advancing melanoma stage.

    Related Experiment Videos

  • Significant differences in sensitization rates were observed between controls and Stage I, and between Stage I and Stage II melanoma (p < 0.001).
  • While a trend was apparent between Stage II and Stage III, contradictory findings in some studies precluded definitive statistical analysis.

    • Conclusions:

    • The findings support the hypothesis that delayed-type hypersensitivity (DTH) immunity is impaired during melanoma progression.
    • These results underscore the potential benefits of immunomodulatory therapies, such as BCG vaccination, DNCB sensitization, and interferon application, in managing melanoma.